Science Explorer Back to mapMap
Discussion
Company · Charlotte · United States

OncoTab (United States)

Research works
4
▼ 100% vs 2018-21
Citations
40
9.0 per fractional work
Top-10% rate
6.1%
all institutions 10.0%
Open access
38%
world 40%

Not ranked overall: OncoTab (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does OncoTab (United States) work in?

In all years, 57% of research at OncoTab (United States) is in Life Sciences, 43% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (52%), Medicine (43%), Immunology and Microbiology (5%). It does 1.5× the world's share of Life Sciences.

Life Sciences57%Health Sciences43%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology252.3%
    2. Immunology and Microbiology04.5%
    1. Medicine243.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from OncoTab (United States)?

The most cited paper from OncoTab (United States) is "Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer" (Vanessa J. Kelly, Shu-ta Wu, Gottumukkala Vijay et al., 2020), with 45 citations. Next come "A tumor specific antibody to aid breast cancer screening in women with dense breast tissue" (31) and "Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice" (22).

Most cited papers
#PaperReleasedCitations
1 Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer Vanessa J. Kelly, Shu-ta Wu, Gottumukkala Vijay et al. · Theranostics Open access 2020 45
2 A tumor specific antibody to aid breast cancer screening in women with dense breast tissue Lopamudra Das Roy, Lloye M. Dillon, Ru Zhou et al. · Genes & Cancer Open access 21 May 2017 31
3 Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice Jennifer M. Curry, Dahlia M. Besmer, Timothy K. Erick et al. · PLoS ONE Open access 6 Nov 2019 22
4 Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma Didier Dréau, Laura Jeffords Moore, Mike Wu et al. · Frontiers in Oncology Open access 30 Apr 2019 19
5 Development and Non-clinical Evaluation of an 111In/225Ac Theranostic for Triple Negative Breast Cancer Ohad Ilovich, Vanessa J. Kelly, Shu-ta Wu et al. · Journal of medical imaging and radiation sciences Dec 2019 3
All 5 most cited papers, with filters and sorting

Which research topics does OncoTab (United States) publish most on?

By volume: Glycosylation and Glycoproteins Research, Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research and Immunotherapy and Immune Responses.

  1. 1 Glycosylation and Glycoproteins Research Molecular Biology 2 works
  2. 2 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 1 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  4. 4 Immunotherapy and Immune Responses Immunology 0 works
  5. 5 Cancer Genomics and Diagnostics Cancer Research 0 works
  6. 6 Pancreatic and Hepatic Oncology Research Oncology 0 works
  7. 7 Cancer and biochemical research Molecular Biology 0 works
  8. 8 Cancer Research and Treatments Biotechnology 0 works
  9. 9 Molecular Biology Techniques and Applications Molecular Biology 0 works
  10. 10 Inflammatory mediators and NSAID effects Pharmacology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available38.2%not open61.8%

World: 40% of research is openly available.

How has OncoTab (United States)'s research output changed?

Output in 2022-2025 was 100% lower than in 2018-2021.

2020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Charlotte

All research institutions in Charlotte

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about OncoTab (United States). Posts are plain text and can be reported.